

MOL #100982

Title Page

α -Conotoxins identify the $\alpha 3\beta 4^*$ subtype as the predominant nicotinic acetylcholine receptor expressed in human adrenal chromaffin cells

Arik J. Hone, J. Michael McIntosh, Layla Azam, Jon Lindstrom, Linda Lucero, Paul Whiteaker, Juan Passas, Jesús Blázquez, & Almudena Albillos

Departamento de Farmacología y Terapéutica, Universidad Autónoma de Madrid, Madrid, Spain (A.J.H, A.A.); Departments of Biology and Psychiatry, University of Utah, Salt Lake City, Utah, USA (J.M.M, L.A.); George E. Whalen Veterans Affairs Medical Center, Salt Lake City, Utah, USA (J.M.M); Department of Neuroscience, University of Pennsylvania Medical School, Philadelphia, Pennsylvania (J.L); Division of Neurobiology, Barrow Neurological Institute, Phoenix, Arizona, USA (L.L., P.W.); Hospital Doce de Octubre, Madrid, Spain (J.P.); Hospital Clínico San Carlos Madrid, Spain (J.B.).

MOL #100982

Running Title Page

Running title: α -Conotoxins identify $\alpha 3\beta 4$ nAChRs in chromaffin cells

Text pages: 44

Tables: 5

Figures: 9

References: 55

Words in the abstract: 218

Words in the Introduction: 749

Words in the Discussion: 1500

Abbreviations: Acetylcholine, ACh; ACC, adrenal chromaffin cells; α -conotoxin, α -Ctx; nicotinic acetylcholine receptor, nAChR; PCR, polymerase chain reaction; RT-PCR, Reverse-transcriptase PCR; qPCR, quantitative real-time PCR; two-electrode voltage-clamp, TEVC.

Corresponding author:

Almudena Albillos

Calle Arzobispo Morcillo, 4

Departamento de Farmacología y Terapéutica

Facultad de Medicina

Universidad Autónoma de Madrid

Madrid, Spain 28029

Phone: + (34) 91 497 53 48

Fax: + (34) 91 49 53 97

Email: almudena.albillos@uam.es

MOL #100982

Abstract

Ligands that selectively inhibit human $\alpha 3\beta 2$ and $\alpha 6\beta 2$ nicotinic acetylcholine receptor (nAChRs) and not the closely related $\alpha 3\beta 4$ and $\alpha 6\beta 4$ subtypes are lacking. Current α -conotoxins (α -Ctxs) that discriminate among these nAChR subtypes in rat fail to discriminate among the human receptor homologs. Here we describe the development of α -Ctx LvIA(N9R,V10A) that is 3,000-fold more potent on oocyte expressed human $\alpha 3\beta 2$ than $\alpha 3\beta 4$ and 165-fold more potent on human $\alpha 6/\alpha 3\beta 2\beta 3$ than $\alpha 6/\alpha 3\beta 4$ nAChRs. This analog was used in conjunction with three other α -Ctx analogs and patch-clamp electrophysiology to characterize the nAChR subtypes expressed by human adrenal chromaffin cells. LvIA(N9R,V10A) showed little effect on the acetylcholine-evoked currents in these cells at concentrations expected to inhibit nAChRs with $\beta 2$ ligand-binding sites. In contrast, the $\beta 4$ -selective α -Ctx BuIA(T5A,P6O) inhibited >98% of the acetylcholine-evoked current indicating that most of the heteromeric receptors contained $\beta 4$ ligand-binding sites. Additional studies using the $\alpha 6$ -selective α -Ctx PeIA(A7V,S9H,V10A,N11R,E14A) indicated that the predominant heteromeric nAChR expressed by human adrenal chromaffin cells is the $\alpha 3\beta 4^*$ subtype (asterisk indicates the possible presence of additional subunits). This conclusion was supported by PCR experiments of human adrenal medulla gland and of cultured human adrenal chromaffin cells that demonstrated prominent expression of RNAs for $\alpha 3$, $\alpha 5$, $\alpha 7$, $\beta 2$, and $\beta 4$ subunits and a low abundance of RNAs for $\alpha 2$, $\alpha 4$, $\alpha 6$, and $\alpha 10$ subunits.

MOL #100982

Introduction

nAChRs are ligand-gated ion channels composed of five individual subunits and can be classified into two broad categories, homomeric and heteromeric, based on whether the receptors are assembled from one gene product or from two or more gene products, respectively. In humans there are sixteen different nAChR genes designated $\alpha 1$ - $\alpha 7$, $\alpha 9$, $\alpha 10$, $\beta 1$ - $\beta 4$, δ , ϵ , and γ (for a review of nAChRs see (Albuquerque et al., 2009)). Highly selective ligands that discriminate between the various human nAChR subtypes are lacking which makes pharmacological identification of individual subtypes difficult. This is particularly problematic for the more closely related subtypes such as those that contain $\alpha 3$ or $\alpha 6$ subunits.

Peptides isolated from the venom of marine cone snails, and one subclass in particular, the α -Ctxs, have been particularly useful in developing ligands that selectively target one nAChR subtype over another. For example, α -Ctx TxIB is highly selective for rat $\alpha 6/\alpha 3\beta 2\beta 3$ nAChRs and shows very little activity on other subtypes (Luo et al., 2013). α -Ctx PnIA is a peptide similar in sequence to TxIB and is selective for rat $\alpha 3\beta 2$ and $\alpha 6\beta 2$ nAChRs over the $\alpha 3\beta 4$ and $\alpha 6/\alpha 3\beta 4$ subtypes (Hone et al., 2012a; Luo et al., 1999). α -Ctx LvIA is a newly discovered peptide that shows some selectivity for $\alpha 3\beta 2$ over the $\alpha 3\beta 4$ subtype (Luo et al., 2014). The amino acid sequences of these small peptides are all similar but vary in key positions that are known to be critical for activity. Importantly, they can be modified by substituting one or more of their amino acids to produce analogs with increased potency and selectivity and several have recently been developed that are highly selective for various rodent nAChR subtypes. For example, PeIA(S9H,V10A,E14N) shows a high degree of selectivity for rat $\alpha 3\beta 2$ and $\alpha 6\beta 2$ nAChRs over the $\alpha 3\beta 4$ and $\alpha 6\beta 4$ subtypes (Hone et al., 2012b) and PeIA(A7V,S9H,V10A,N11R,E14A) selectively inhibits $\alpha 6$ -containing nAChRs over other

MOL #100982

subtypes (Hone et al., 2013). The margins of selectivity of most of these peptides for human receptors, however, are much narrower (unpublished observation) making discrimination among human nAChR subtypes difficult. We took advantage of the modest selectivity of LvIA and made two substitutions in the peptide's amino acid sequence to further increase its potency and selectivity for human $\alpha 3\beta 2$ and $\alpha 6\beta 2$ nAChRs then used this analog to probe for the expression of these two subtypes in human adrenal chromaffin cells.

Chromaffin cells of the adrenal gland are neuroendocrine cells that release catecholamines and other substances into the bloodstream during the flight-or-fight response or as a reaction to a perceived stressful situation. These cells are of neural crest origin and have many of the features of neurons including the ability to fire action potentials and release neurotransmitters, particularly catecholamines. Activation of nAChRs by ACh released from the splanchnic nerve is sufficient to depolarize the adrenal chromaffin cell membrane and activate voltage-gated ion channels including calcium channels. The influx of calcium ions through nAChRs and voltage-gated calcium channels facilitates the fusion of synaptic vesicles with the plasma membrane to promote the release of vesicular content (Mollard et al., 1995; Perez-Alvarez et al., 2012a). Rodent (Di Angelantonio et al., 2003; Gahring et al., 2014) and bovine (Campos-Caro et al., 1997; Criado et al., 1997) adrenal chromaffin cells have been reported to express a variety of nAChR subtypes including $\alpha 7$, $\alpha 3\beta 4^*$, $\alpha 3\beta 2^*$, and $\alpha 4\beta 2^*$, whereas in primates the reported receptor subtype(s) have included $\alpha 7$ and $\alpha 6\beta 4^*$ (Hernandez-Vivanco et al., 2014; Perez-Alvarez et al., 2012a; Perez-Alvarez et al., 2012b). Given the number of nicotinic compounds used clinically it is critical to identify all of the subtypes expressed by human adrenal chromaffin cells and to assess their pharmacology. In this study we synthesized a novel α -Ctx analog that is potent and highly selective for human $\alpha 3\beta 2$ and $\alpha 6\beta 2$ nAChRs over

MOL #100982

the $\alpha 3\beta 4$ and $\alpha 6\beta 4$ subtypes. This analog, LvIA(N9R,V19A), in conjunction with a panel of three other α -Ctxs allowed us to identify the $\alpha 3\beta 4^*$ subtype as the predominant nAChR expressed by human adrenal chromaffin cells. Previous studies were inconclusive regarding the presence of nAChRs with $\beta 2$ ligand-binding sites in these cells and in the present study we demonstrate that in fact there are likely to be few nAChRs of this type present. Furthermore, we show that the $\alpha 3\beta 4^*$ nAChRs in these cells contain two $\alpha 3$ - $\beta 4$ ligand-binding sites and suggest that the stoichiometry of the receptor is likely $(\alpha 3\beta 4)_2$ with a 5th auxiliary subunit that has yet to be identified. These studies highlight the utility of α -Ctxs for characterizing the possible nAChRs expressed by a given cell type.

MOL #100982

Materials and Methods.

Reagents. Acetylcholine chloride, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), amphotericin B, penicillin/streptomycin, protease type XIV, collagenase Type I, poly-D-lysine hydrobromide, Red Blood Cell Lysis solution, dimethylsulfoxide, and all salts were purchased from Sigma-Aldrich (St. Louis, MO, USA). Dulbecco's Modified Eagle's Medium (DMEM) and Glutamax were purchased from Life Technologies (Carlsbad, CA, USA). Fetal bovine serum was from LabClinics (Barcelona, Spain) and the D-glucose from Panreac (Barcelona, Spain). Amino acids used in peptide synthesis were obtained from AAPPTec (Louisville, KY, USA).

Peptide Synthesis. The α -Ctxs BuIA(T5A,P6O) and ArIB(V11L,V16D) were synthesized at the University of Utah DNA/Peptide sequencing core facility according to the procedures described in (Cartier et al., 1996). α -Ctxs LvIA(N9R,V10A) and PeIA(A7V,S9H,V10A,N11R,E14A) were synthesized using an AAPPTec Apex 396 automated peptide synthesizer according to the procedures described in (Hone et al., 2012b). The peptide masses were verified by matrix-assisted laser desorption ionization/time-of-flight mass spectrometry, which was performed at the Salk Institute for Biological Studies (La Jolla, CA, USA).

Two-Electrode Voltage-Clamp Electrophysiology of *Xenopus laevis* Oocytes. Detailed methods for conducting electrophysiology of *Xenopus* oocytes and the pharmacological assessment of the activities of α -Ctxs on heterologously expressed nAChRs have been previously described (Hone et al., 2009). Briefly, stage IV-V oocytes were injected with equal ratios of capped cRNA encoding human nAChR subunits prepared using the mMessage mMachine in vitro transcription kit (Ambion, Austin, TX, USA). The α 3, α 4, β 2, β 3, and β 4 clones were provided by Jim Garrett (Cognetix, Salt Lake City, UT, USA). The β 4- α 3- β 4- α 3- α 5(D)

MOL #100982

concatemer was prepared as previously described (George et al., 2012). Coinjection of human $\alpha 6$ subunit cRNA with cRNA for the $\beta 2$, $\beta 3$, or $\beta 4$ subunits results in few or no functional receptors (Kuryatov and Lindstrom, 2011; Kuryatov et al., 2000; McIntosh et al., 2004). Several strategies have been employed to achieve functional expression including concatenated subunits as well as chimeras of $\alpha 6$ and other α subunits. We used an $\alpha 6/\alpha 3$ construct where the first 207 amino acids of the $\alpha 3$ subunit are replaced with those of the $\alpha 6$ subunit ligand-binding domain (Kuryatov et al., 2000) and an $\alpha 6_{M211L, \text{cyt}\alpha 3}$ construct where the Met at position 211 is replaced by a Leu residue and the intracellular loop between transmembranes three and four is replaced with that of the $\alpha 3$ subunit (Ley et al., 2014). For brevity, we use “ $\alpha 6\beta 4$ constructs” throughout the rest of the manuscript to describe data where both $\alpha 6_{M211L, \text{cyt}\alpha 3}\beta 4$ and $\alpha 6/\alpha 3\beta 4$ were used to obtain α -Ctx values. Both of the $\alpha 6$ constructs and the $\beta 3$ - $\alpha 6$ - $\beta 2$ - $\alpha 4$ - $\beta 2$ concatemer were prepared as previously described (Kuryatov and Lindstrom, 2011). Human $\alpha 6/\alpha 3$ and human $\beta 4$ were ligated into the digested pSGEM vector by T4 DNA ligase. The ligation reactions were transformed in DH10B chemically competent cells and plated on Ampicillin LB plates and incubated overnight at 37°C. The following day, the cells were incubated in inoculated Ampicillin-containing LB at 37°C in a shaker overnight. The DNA for both clones was isolated using the Qiaprep Spin Miniprep kit (Qiagen, Valencia, CA) and linearized with *NheI* restriction enzyme prior to RNA transcription. The linearized DNA was purified using the Qiaquick PCR purification kit (Qiagen, Valencia, CA) and RNA was synthesized using the Ambion T7 mMessage mMachine RNA transcription kit (Life Technologies, Carlsbad, CA). The RNA was subsequently purified using the RNeasy mini kit (Qiagen, Valencia, CA). The concentration of the RNA was determined by UV spectroscopy. Oocytes were subsequently injected with the cRNA and electrophysiology experiments were conducted 1-5 days after injection. To record ACh-evoked currents, the oocyte

MOL #100982

membranes were voltage-clamped at a holding potential of -70 mV with a Warner Instruments OC-725 series amplifier (Warner, Instruments, Hamden, CT, USA) then stimulated with 1-sec pulses of ACh once every 60 sec. A concentration of 300 μ M ACh was used for all subtypes to elicit a maximal response and to compare the α -Ctx IC₅₀ values obtained in human adrenal chromaffin cells. The α -Ctxs were suspended in extracellular solution (ND96) and perfusion applied for concentrations \leq 1 μ M or in a static bath for 5 min for concentrations $>$ 1 μ M.

End-point PCR analysis of nAChR subunit mRNA. Total RNA was extracted from the adrenal medulla of 4 donors (age 64 \pm 15 years, SDM) or from cultured human adrenal chromaffin cells from 3 donors (age 58 \pm 8 years, SDM) according to the manufacturers' instructions using an Ambion RNAqueous-4PCR kit (cat. #AM1914) and subsequently treated with DNase I to degrade genomic DNA. The purity of the RNA was assessed by measuring the A₂₆₀/A₂₈₀ ratio using a NanoDrop spectrophotometer. cDNA was reverse transcribed using the High Capacity cDNA Reverse Transcription Kit (cat. #4368814, Applied Biosystems, Foster City, CA, USA) following the manufacturer's instructions. Ten μ l of the RNA was used in a total reaction volume of 20 μ l. The cycling conditions for the reverse-transcription were as follows: step 1, 25°C for 10 min; step 2, 37°C for 120 min; and step 3, 85°C for 5 min and were achieved using a PTC-200 peltier thermal cycler (MJ Research, Waltham, MA, USA). In some samples the reverse transcriptase was omitted to further assess for genomic DNA contamination in the subsequent reverse-transcriptase polymerase chain reaction (RT-PCR) analyses.

End-point RT-PCR analysis was performed using the Qiagen Taq PCR Master Mix Kit (Qiagen, Valencia, CA) following the manufacturer's instructions. Briefly, 2.5 μ l of cDNA template were added to the Master Mix solution containing sense and antisense primers (final concentration of 500 nM for each primer) in a total reaction volume of 50 μ l. Negative controls for each reaction

MOL #100982

were performed by omission of the cDNA template. Several primer sets designed to target *Homo sapiens* sequences were evaluated (Carlisle et al., 2004; Lips et al., 2005; Liu et al., 2009a; West et al., 2003). Each primer pair was aligned with their respective nicotinic subunit DNA and RNA sequences to verify that the primers spanned introns. All of primers used for generation of the results presented here spanned an intron with exception of primers for the $\alpha 9$ subunit. The primers were synthesized by the University of Utah Sequencing and Genomics Core Facility at the University of Utah (Salt Lake City, UT, USA). The PCR was performed in a PTC-200 thermal cycler using an initial 5 min denaturation step at 95°C followed by 35 cycles of denaturation at 94°C for 30 s, 55-60°C for 30 s for annealing, 72°C for 45 s for extension, with a final extension step at 72°C for 10 min. Following PCR, the reactions were analyzed by gel (1.5% agarose wt/vol) electrophoresis, stained and visualized with ethidium bromide. A summary of the primers used to assess the presence of the different nAChR subunit mRNAs and the RT-PCR conditions used is provided in Table 3.

Quantitative real-time PCR (qPCR) was performed to quantify the presence of mRNA transcripts. qPCR was performed using inventoried TaqMan® Gene Expression Assays (Thermo Fisher Scientific, Inc. Waltham, MA) according to manufacturer's instructions. (See Table 4 for a list of hydrolysis probe assay ID numbers and context sequences representing the human nAChR and reference genes analyzed in this study). With the exception of GAPDH and ACTB, all probe sets spanned an intron. DNase I-treated human brain reference total RNA pooled from multiple donors and several brain regions was purchased from Ambion (cat. #AM6050). Up to 2 ug of total RNA was reverse-transcribed into cDNA using the SuperScript VILO cDNA Synthesis Kit (Thermo Fisher Scientific, Inc.). Each 10 ul qPCR reaction was performed in triplicate and assembled using 5 ul of TaqMan 2X Fast Advanced Master Mix (containing

MOL #100982

AmpliTaq® Fast DNA Polymerase, uracil-N glycosylase (UNG), dNTPs with dUTP, and ROX™ dye (passive reference)), 0.5ul of a 20X hydrolysis probe set, and 4.5 ul of nuclease-free water containing 20 ng of cDNA (derived from RNA concentrations). A minus template control was run for each probe set. Samples were prepared in Fast Optical 96-well plates (Thermo Fisher, Inc. Cat. #4346906) and the gene targets were amplified using the Applied Biosystems QuantStudio Flex 6 real-time thermocycler. The qPCR thermal cycling program used was as follows: 1 cycle of 50° C for 2 minutes followed by 95°C for 20 seconds (to activate, and then inactivate UNG which degrades any carry-over DNA), 40 cycles of 1 second denaturation at 95°C followed by 20 seconds of annealing and extension at 60°C. Cq values for each reaction were extracted using QuantStudio software in order to calculate relative gene expression levels and compared to total human brain using the $2^{-\Delta\Delta Cq}$ method (Livak and Schmittgen, 2001). For this study, four reference genes were tested (GAPDH, ACTB, UBC, B2M) and the resulting Cq means were exported to the online reference gene stability analyzer, RefFinder (<http://150.216.56.178>). Briefly, gene stability was analyzed using the Delta CT (Silver et al., 2006), BestKeeper (Pfaffl et al., 2004), Normfinder (Andersen et al., 2004), and Geonorm (Vandesompele et al., 2002) methods to generate a comprehensive stability ranking of all four reference genes. From this analysis, GAPDH and ACTB produced similar high stability rankings and thus were chosen for geometric mean calculations and qPCR single- and double-normalization. Single-normalization, $\log_{10}(2^{-\Delta Cq})$ where $\Delta Cq = (\text{mean Cq nAChR gene} - \text{geometric mean Cq reference genes})$, was also employed to assess more directly the relative abundance of each nAChR gene compared to control genes within and between single samples in the absence of brain reference tissue. Statistical analysis of nAChR gene expression was determined using an ANOVA and a Bonferroni post hoc test. Differences were considered

MOL #100982

significant if the *p* value was less than 0.05. All data are reported as the mean \pm standard error of the mean (SEM).

Human Adrenal Chromaffin Cell Isolation and Culture. Adrenal chromaffin cells were isolated from six male, age 58 ± 13 years (SDM), and one 35 year old female organ donors. To isolate the chromaffin cells, the glands were perfused with a saline solution (154 mM NaCl, 5.6 mM KCl, 3.6 mM NaHCO₃, 5.6 mM D-glucose, and 5 mM HEPES; (pH was adjusted to 7.4 with NaOH and the observed osmolarity was 325 mOsm) through the suprarenal vein until the solution was clear and blood free then with 2 ml of saline containing 1 mg/ml protease type XIV. The glands were then placed in a 50 ml conical tube, covered with saline solution, and incubated for 10 min at 37° C followed by a second perfusion with protease and additional 10 min incubation at 37° C. Following treatment with protease, the glands were placed in a 150 mm Petri dish and bisected sagittally then opened by a coronal incision. The medullary tissue was scraped out of the gland and transferred to a conical tube partially filled with 30 ml of saline solution containing 2 mg/ml collagenase Type I. The medullary tissue was then incubated for 60 min at 37° C in a water bath with intermittent trituration every 5 min with a plastic Pasteur pipette. Following incubation with collagenase, 10 ml of saline solution was added to the cell suspension then filtered first through a 200 μ m nylon mesh followed by an 80 μ m mesh. The isolated cells were centrifuged at 200 x g for 10 min, the supernatant removed and the cell pellet suspended in 1 ml of Red Blood Cell Lysis Buffer for 60 sec after which, 39 ml of saline was added to terminate the actions of the lysis buffer. Lastly, the cells were centrifuged at 200 x g for 5 min, the supernatant removed and the cells suspended in DMEM containing 10% fetal bovine serum, 200 μ M Glutamax, 100 U/ml penicillin, and 0.1 mg/ml streptomycin. Five-hundred μ l of the cell suspension was added to each well of a 24 well culture plate containing glass coverslips that had

MOL #100982

been treated with 0.1 mg/ml poly-D-lysine. The cells were maintained at 37° C in an incubator under an atmosphere of 95% air and 5% CO₂ for up to 7 days. The culture medium was changed daily by exchanging approximately 70% of the solution with fresh medium.

Patch-Clamp Electrophysiology of Chromaffin Cells. To conduct electrophysiology experiments, the coverslips were placed in a glass bottom chamber and continuously gravity perfused with extracellular solution (145 mM NaCl, 5 mM KCl, 2 mM CaCl₂, 1 mM MgCl₂, 10 mM D-glucose, and 10 mM HEPES; pH adjusted to 7.4 with NaOH; observed osmolarity 325 mOsM) at a flow rate of 1.5 ml/min by means of a polyethylene tube with an inner diameter of 0.58 mm. The outlet of this tube was placed close to the cell of interest to ensure rapid solution exchange. Glass electrodes were pulled from borosilicate glass capillaries (Kimbal Chase, cat. #3400-99) using a P97 pipette puller (Sutter Instruments, Novato CA, USA). These electrodes had resistances between 1.5 and 2.5 MΩ when filled with an internal electrode solution composed of 145 mM K-glutamate, 10 mM NaCl, 1 mM MgCl₂, 10 mM D-glucose, and 10 mM HEPES (pH adjusted to 7.2 with KOH; observed osmolarity 322 mOsM). To initiate whole-cell recordings, a stock solution of 0.5 mg/ml amphotericin B was prepared daily in dimethylsulfoxide and 5 μl of this stock solution was added to 500 μl of intracellular solution and ultrasonicated immediately before use. All experiments were performed under a sodium lamp for light. A HEKA EPC10 amplifier (HEKA Elektronik, Lambrecht, Germany) was used to record ACh-evoked responses. Analysis of the α-Ctx activity was performed only on cells where the series resistance obtained was < 20 MΩ and in general, resistances between 10 and 15 MΩ were achieved and were compensated electronically up to 94% to minimize voltage errors. ACh was applied using a multi barreled pipette that was constructed using polyethylene tubing with an inner diameter of 0.4 mm. These tubes coalesced to a single outlet tube with a 0.28 mm inner

MOL #100982

diameter and had a flow rate approximately 850 μ l/min. The agonist pulses were delivered by gravity and were controlled by a valve controller triggered by the amplifier. The activities of the antagonists were determined by applying 200 ms pulses of ACh once every 3 min until a steady baseline response was achieved. The control solution was then switched to one containing the antagonist of interest and was perfused until a steady state level of inhibition was observed. The peak amplitudes of three control responses were averaged and the level of inhibition by the antagonist was determined by dividing the peak amplitude of the response in the presence of the antagonist by the averaged control response to obtain a “percent response” value. Human adrenal chromaffin cells are known to express α 7-containing nAChRs but account for <10% of the whole-cell response to ACh (Perez-Alvarez et al., 2012a). In this study, our interest was focused on the predominant heteromeric subtype expressed therefore the α 7 antagonist α -Ctx ArIB(V11L,V16D) was included in all solutions at a concentration of 100 nM (Hone et al., 2012a; Whiteaker et al., 2007). For simplicity, we refer to heteromeric subtypes throughout the manuscript as those that do not include α 7 subunits.

Data Analysis. All statistical comparisons of antagonist data, concentration-response analyses, and qPCR-determined gene expression levels were performed using GraphPad Prism (La Jolla, CA, USA). Current traces were rendered using IGOR Pro (WaveMetrics Inc., Lake Oswego, OR, USA). Images for gel electrophoresis were processed using ImageJ (U. S. National Institutes of Health, Bethesda, Maryland, USA).

Results.

MOL #100982

α -Ctx LvIA(N9R,V10A) is a potent and selective ligand for human $\alpha 3\beta 2$ and $\alpha 6\beta 2$ -containing nAChRs expressed in *Xenopus laevis* oocytes. As previously discussed α -Ctxs TxIB, PnIA, and LvIA show some degree of selectivity for particular nAChR subtypes. Table 1 shows the sequences of these peptides and compares their selectivity profiles. Note that many of the amino acids are strictly conserved while others are highly variable. The residues that vary likely account for the observed differences in the peptides' selectivity profiles. Indeed, we have previously shown that specific positions in the sequence of α -Ctx PeIA are important for determining potency and selectivity for $\beta 2$ - over $\beta 4$ -containing subtypes and can be substituted with other amino acids to generate analogs with more favorable selectivity profiles. For example, substituting the Val in the 10th position of PeIA with Ala, the residue found in this position in PnIA, increases the selectivity for $\alpha 3\beta 2$ over $\alpha 3\beta 4$ by >1,000-fold and by >100-fold for $\alpha 6/\alpha 3\beta 2\beta 3$ over $\alpha 6/\alpha 3\beta 4$ nAChRs (Hone et al., 2012b). Substituting Ser9 with Arg, the residue found in this position in TxIB, results in an 1,800-fold increase in selectivity for $\alpha 6/\alpha 3\beta 2\beta 3$ over $\alpha 6/\alpha 3\beta 4$ nAChRs (Hone et al., 2013). Thus, taking cues from the natural diversity found in the α -Ctxs shown in Table 1 and from our studies with PeIA, we synthesized an LvIA analog that was expected to show greater selectivity for human $\alpha 3\beta 2$ and $\alpha 6\beta 2$ nAChRs over the $\alpha 3\beta 4$ and $\alpha 6\beta 4$ subtypes. Two substitutions in the amino acid sequence of LvIA were made to generate LvIA(N9R,V10A). Verification of the peptide synthesis was confirmed by mass spectrometry. The calculated monoisotopic mass for LvIA(N9R,V10A) is 1693.64 Da and the observed monoisotopic mass was determined to be 1693.97 Da. The peptide was then tested on a panel of human nAChRs expressed in *Xenopus* oocytes that included $\alpha 3\beta 2$, $\alpha 3\beta 4$, $\beta 4\alpha 3\beta 4\alpha 3\alpha 5(D)$, $\alpha 4\beta 2$, $\alpha 4\beta 4$, $\alpha 6/\alpha 3\beta 2\beta 3$, $\beta 3\alpha 6\beta 2\alpha 4\beta 2$, $\alpha 6/\alpha 3\beta 4$, and $\alpha 6_{M211L,cyt\alpha 3}\beta 4$. As shown in Figure 1, this analog was >3,000-fold more potent on $\alpha 3\beta 2$ than $\alpha 3\beta 4$, and was between 85-245-fold more potent on

MOL #100982

$\alpha 6\beta 2$ -containing nAChRs over the $\alpha 6\beta 4$ constructs. In addition, the analog showed some activity on the $\alpha 4\beta 2$ subtype but very little activity on the $\alpha 4\beta 4$ subtype (Fig. 1). Thus, when used at a concentration of 100 nM >90% of responses mediated by $\alpha 3\beta 2$ or $\alpha 6\beta 2$ nAChRs were inhibited while inhibiting <5% of the responses from $\beta 4$ -containing nAChRs.

The α -Ctx analog BuIA(T5A,P6O) discriminates between human $\beta 2$ and $\beta 4$ subunit-containing nAChRs. In order to dissect the responses mediated by $\beta 2$ -containing nAChRs from those mediated by $\beta 4$ -containing nAChRs, a ligand is needed that discriminates between the different nAChRs that contain these subtypes. We therefore assessed the activity of α -Ctx BuIA(T5A,P6O) which has been shown to selectively inhibit rat and mouse $\alpha 6\beta 4$ and $\alpha 3\beta 4$ nAChRs over other subtypes (Azam et al., 2010). When tested on human nAChRs expressed in *Xenopus* oocytes, we found that this analog was >1,000-fold more potent on the $\alpha 6\beta 4$ constructs than on $\alpha 3\beta 2$, $\alpha 4\beta 2$, $\alpha 4\beta 4$, $\alpha 6/\alpha 3\beta 2\beta 3$, and $\beta 3\alpha 6\beta 2\alpha 4\beta 2$ nAChRs (Fig. 2). Additionally, BuIA(T5A,P6O) was >20-fold more potent on the $\alpha 6\beta 4$ constructs than on $\alpha 3\beta 4$ and $\beta 4\alpha 3\beta 4\alpha 3\alpha 5(D)$ nAChRs (Fig. 2). Thus, this ligand can be used to selectively inhibit $\alpha 3\beta 4$ and $\alpha 6\beta 4$ nAChRs while only minimally inhibiting those that contain the $\beta 2$ subunit.

α -Ctxs BuIA(T5A,P6O) and LvIA(N9R,V10A) demonstrate that the predominant functional heteromeric nAChRs expressed in human adrenal chromaffin cells only contain $\beta 4$ ligand-binding sites. A series of experiments were conducted using the α -Ctx analogs presented in Figs. 1 and 2 to assess the presence of $\beta 2$ or $\beta 4$ subunits at the $\alpha(+)\beta(-)$ subunit interface. We included α -Ctx ArIB(V11L,V16D) in the perfusion solution to ensure that only non $\alpha 7$ nAChRs were being assessed. This $\alpha 7$ antagonist has previously been shown to be a potent inhibitor of human $\alpha 7$ nAChRs (Innocent et al., 2008). However, since this α -Ctx had not been tested on heteromeric human subtypes, we first tested it on oocyte expressed nAChRs and

MOL #100982

found that as for rat nAChRs, ArIB(V11L,V16D) showed very little activity on non $\alpha 7$ human subtypes even at a concentration of 10 μM (Fig. 3). Therefore, in the presence of 100 nM ArIB(V11L,V16D) any inhibition by BuIA(T5A,P6O) would be attributed to the presence of $\alpha 3\beta 4$ or $\alpha 6\beta 4$ nAChRs. BuIA(T5A,P6O) was then tested in human adrenal chromaffin cells and found to inhibit the ACh-evoked responses with an IC_{50} value of ~ 50 nM (Fig. 4A). At 1 μM , the responses were inhibited by $97 \pm 0.6\%$ ($n=7$) indicating that most of the heteromeric nAChRs present contained $\beta 4$ ligand-binding sites (Fig. 4A).

Next we used LvIA(N9R,V10A) to determine if receptors containing $\beta 2$ ligand-binding sites were present. As shown in Figure 4A, significant inhibition of the ACh-evoked current by LvIA(N9R,V10A) was only observed at concentrations greater than those required for inhibition of $\beta 2$ -containing nAChRs (>100 nM). Examples of current traces showing the inhibition produced by the two α -Ctxs are shown in Figure 4B and C. Most heteromeric human nAChR subtypes, with the exception of the $\alpha 9\alpha 10$ subtype, fall into two categories that contain either $\beta 2$ or $\beta 4$ subunits but mixed subtypes that contain both $\beta 2$ and $\beta 4$ ligand-binding sites have been shown in to be present in several brain regions in rodents (Azam and McIntosh, 2006; Grady et al., 2009; Turner and Kellar, 2005; Whiteaker et al., 2009). Binding of a single α -Ctx molecule to a nAChR subunit interface is sufficient to block the allosteric transitions required for ion channel opening (Talley et al., 2006) and binding to a target site can occur with high affinity without regard to composition of other binding sites in the receptor complex. Examples include inhibition of 1/5 sites in an $\alpha 7$ homopentamer, binding to the α - ϵ or α - δ interface in a muscle type nAChR, or binding to the $\alpha 6$ - $\beta 2$ interface in an $\alpha 6\beta 2\alpha 4\beta 2\beta 3$ nAChR (Gotti et al., 2005; Groebe et al., 1995; Jacobsen et al., 1999; Sine et al., 1995; Teichert et al., 2005). Thus, the affinities of the LvIA and BuIA analogs for their respective binding to would be expected to be

MOL #100982

similar for a mixed $\beta 2$ and $\beta 4$ nAChR subtype. We tested the LvIA and the BuIA analogs on the same cells to probe for nAChR with mixed $\beta 2$ and $\beta 4$ ligand-binding sites and observed very little inhibition by LvIA(N9R,V10A) at 100 nM (Fig. 4D). After washout, the responses were nearly completely inhibited by 1 μ M BuIA(T5A,P6O) (Fig. 4E). These experiments suggest that human adrenal chromaffin cells are unlikely to express significant levels of functional heteromeric nAChRs on the cell surface that contain $\beta 2$ -ligand binding sites. These experiments, however, do not exclude the possibility of a $\beta 2$ subunit in the auxiliary 5th position of the $\alpha 3\beta 4^*$ nAChR complex.

Human adrenal chromaffin cells have been reported to express $\alpha 6\beta 4^*$ nAChRs (Perez-Alvarez et al., 2012b) yet there are some inconsistencies between α -Ctx IC₅₀ values for inhibition of human adrenal chromaffin cell nAChRs and values for human $\alpha 6/\alpha 3\beta 4$ nAChRs heterologously expressed in *Xenopus* oocytes (Hernandez-Vivanco et al., 2014). Similarly, during the course of the testing of BuIA(T5A,P6O) and LvIA(N9R,V10A), we observed that the IC₅₀ values we obtained in human chromaffin cells were also somewhat different than the values we obtained using the $\alpha 6\beta 4$ constructs expressed in *Xenopus* oocytes (Figs. 1, 2 and 5). Thus, we chose an additional α -Ctx, namely PeIA(A7V,S9H,V10A,N11R,E14A) (Hone et al., 2013), that has been demonstrated to be 275-fold more potent on rat $\alpha 6\beta 4$ than $\alpha 3\beta 4$ nAChRs expressed in *Xenopus* oocytes and thus offers superior selectivity for $\alpha 6\beta 4$ over $\alpha 3\beta 4$ compared to BuIA(T5A,P6O). The activity of this ligand on human nAChR subtypes had also not previously been assessed therefore we tested the peptide on a panel of human nAChRs expressed in *Xenopus* oocytes to ensure that this peptide retained its selectivity for human $\alpha 6$ -containing subtypes. PeIA(A7V,S9H,V10A,N11R,E14A) potently inhibited human $\alpha 6_{M211L,cy\alpha 3}\beta 4$ nAChRs with an IC₅₀ value of 1.6 nM, a value >2,900-fold lower than the IC₅₀ value for the $\alpha 3\beta 4$ subtype

MOL #100982

(Fig. 5A). The peptide also inhibited $\alpha 6/\alpha 3\beta 2\beta 3$ and $\beta 3\alpha 6\beta 2\alpha 4\beta 2$ receptors with low nM potencies but μM concentrations were required to inhibit the $\alpha 3\beta 2$ subtype (Fig. 5A) confirming that the peptide retained its selectivity for human $\alpha 6$ -containing subtypes. When we tested this PeIA analog for inhibition of the ACh-evoked currents in human adrenal chromaffin cells, inhibition was observed only at concentrations of 100 nM or higher suggesting that there were few $\alpha 6\beta 4$ nAChRs present (Fig. 5A). In addition to the difference in IC_{50} values between oocyte expressed human $\alpha 3\beta 4$ and $\alpha 6_{\text{M211L,cyt}\alpha 3}\beta 4$ nAChRs, the kinetics for inhibition were strikingly different. Inhibition equilibrium of $\alpha 3\beta 4$ nAChRs by IC_{50} concentrations of PeIA(A7V,S9H,V10A,N11R,E14A) required ~ 1 min of toxin exposure whereas inhibition of $\alpha 6_{\text{M211L,cyt}\alpha 3}\beta 4$ nAChRs required ~ 15 min to reach steady state equilibrium (Fig. 5B). Furthermore, recovery from inhibition of $\alpha 6_{\text{M211L,cyt}\alpha 3}\beta 4$ nAChRs was markedly slower than for $\alpha 3\beta 4$ nAChRs (Fig. 5B). The kinetics of inhibition and recovery from inhibition of the ACh-evoked responses in human adrenal chromaffin cells closely matched the time frames observed for $\alpha 3\beta 4$ nAChRs expressed in *Xenopus* oocytes (Fig. 5B). A comparison of the α -Ctx potencies for the various human nAChR subtypes expressed in *Xenopus* oocytes as well as their activities in human adrenal chromaffin cells is shown in Table 2.

Human adrenal medulla gland and cultured adrenal chromaffin cells predominantly express mRNAs for $\alpha 3$, $\alpha 5$, $\alpha 7$, $\beta 2$, and $\beta 4$ subunits. The pharmacology experiments suggested that the predominant nAChR expressed by human adrenal chromaffin cells was the $\alpha 3\beta 4$ subtype and that nAChRs containing the $\alpha 6$ subunit were likely few in number. As an additional confirmation, we assessed human adrenal gland tissue for the expression of nAChR subunit mRNAs using both end-point and quantitative real-time PCR methodologies. Total RNA extracted from pieces of adrenal medulla tissue was reverse-transcribed into cDNA and subjected

MOL #100982

to end-point PCR in order to qualitatively probe for the expression of nAChR subunit mRNAs as described in *Materials and Methods*. Figure 6A shows the presence of mRNAs for multiple nAChR subunits including $\alpha 2$, $\alpha 3$, $\alpha 4$, $\alpha 5$, $\alpha 6$, $\alpha 7$, $\alpha 10$, $\beta 2$, and $\beta 4$ subunits. However, signals for $\alpha 3$, $\alpha 5$, $\alpha 7$, $\beta 2$, and $\beta 4$ were relatively stronger than the signals for the other subunits. qPCR was used to quantify and extend the results presented in Fig. 6A. Similar to the end-point RT-PCR results, transcripts for $\alpha 3$, $\alpha 7$ and $\beta 4$ subunits were found to be the most abundant species present (Fig. 6B). Transcripts for $\alpha 5$ and $\beta 2$ were somewhat less abundant while those for $\alpha 2$, $\alpha 6$, and $\alpha 10$ were nearly absent (Fig. 6B). Transcripts for $\alpha 4$, $\alpha 9$, and $\beta 3$ were detected infrequently (data not shown). Internal controls were also performed by comparing the expression levels of $\alpha 2$, $\alpha 3$, $\alpha 4$, $\alpha 5$, $\alpha 6$, $\alpha 7$, $\alpha 10$, $\beta 2$, and $\beta 4$ subunits in adrenal medullary tissue to human brain. These experiments indicated that in adrenal gland, transcripts for $\alpha 3$ were more abundant compared to $\alpha 6$ whereas in human brain $\alpha 6$ were more abundant than $\alpha 3$ (Fig. 6C).

Changes in gene expression may contribute to the differences in mRNAs present in medullary tissue vs. functionally expressed nAChRs in cultured adrenal chromaffin cells. Additionally, immune cells, which are known to express different nAChR subunit mRNAs (Mikulski et al., 2010; Peng et al., 2004), may have been present in the medullary tissue we assessed. Thus, we reassessed the PCR results by performing the experiments on adrenal chromaffin cells isolated and cultured according to the methods used to obtain cells for electrophysiology experiments. In some cultures, 10 μ M AraC was added to inhibit proliferating cells. On day 2, the cells were washed extensively with extracellular solution to remove any non-adhering cells before harvesting the mRNA. qPCR was then performed and similar to the results found in adrenal medulla, the two most abundant mRNA species were $\alpha 3$ and $\beta 4$ (Fig. 7). Transcripts for $\alpha 5$, $\alpha 7$, and $\beta 2$ were also abundant while those for $\alpha 2$, $\alpha 6$, and $\alpha 10$ were nearly

MOL #100982

absent. Transcripts for $\alpha 4$, $\alpha 9$, and $\beta 3$ were detected infrequently (data not shown). These experiments corroborate the electrophysiology experiments identifying $\alpha 3\beta 4^*$ as the predominant heteromeric nAChR subtype expressed by human adrenal chromaffin cells.

MOL #100982

Discussion.

α -Ctxs are widely used as pharmacological tools to study nAChRs. We have observed that some α -Ctxs that distinguish well among rat $\alpha 3\beta 2$, $\alpha 6\beta 2$, and $\alpha 6\beta 4$ nAChRs fail to distinguish among the equivalent human subtypes. We took advantage of the unique sequence of the recently discovered α -Ctx LvIA and, based on our previous work with α -Ctx PeIA, synthesized a new analog that is a potent and highly selective antagonist of human $\alpha 3\beta 2$ and $\alpha 6\beta 2$ nAChRs. This analog, LvIA(N9R,V10A), is particularly selective (>3,000-fold) for $\alpha 3\beta 2$ over $\alpha 3\beta 4$ nAChRs but also has excellent selectivity (~165-fold) for $\alpha 6\beta 2$ -containing nAChRs over the $\alpha 6\beta 4$ nAChR constructs (Fig. 1). Thus, LvIA(N9R,V10A) should prove to be highly useful tool for identifying human $\alpha 3\beta 2$ and $\alpha 6\beta 2$ nAChRs in cells that potentially express both $\beta 2$ and $\beta 4$ subunit-containing subtypes.

In conjunction with three other α -Ctx analogs, LvIA(N9R,V10A) facilitated the identification of $\alpha 3\beta 4^*$ as the predominant functional nAChR subtype expressed by human adrenal chromaffin cells. We arrived at this conclusion based on results obtained using a combination of pharmacology and molecular biology. BuIA(T5A,P6O) is a selective antagonist of oocyte-expressed human $\alpha 3\beta 4$ and $\alpha 6\beta 4$ nAChR constructs and is essentially inactive on all other subtypes at concentrations $\leq 1 \mu\text{M}$ (Fig 2). The fact that across all experiments BuIA(T5A,P6O) (1 μM) inhibited $97 \pm 0.6\%$ (n=13) of the ACh-evoked current in human chromaffin cells suggests that these cells express few nAChRs with $\beta 2$ ligand-binding sites only (Fig. 4A-E). This conclusion is supported by the observation that the currents were insensitive to inhibition by LvIA(N9R,V10A) at concentrations selective for $\alpha 3\beta 2$ and $\alpha 6\beta 2$ subtypes (Fig. 4A). Furthermore, when both α -Ctxs were sequentially tested on the same cells, the LvIA analog inhibited the ACh-evoked currents by only $8.5 \pm 2.2\%$ (n=6) whereas the BuIA analog inhibited

MOL #100982

the currents by $98.0 \pm 0.3\%$ ($n=6$) (Fig. 4D and E). These data suggest that nAChRs with both $\beta 2$ and $\beta 4$ ligand-binding sites are also likely to be few in number.

We previously showed that α -Ctx PeIA(A7V,S9H,V10A,N11R,E14A) was >200-fold more potent on rat $\alpha 6\beta 4$ nAChRs than the $\alpha 3\beta 4$ subtype (Hone et al., 2013). Similarly, we found that this peptide was ~600-fold more potent on human $\alpha 6_{M211L,\alpha 3_{\text{cyt}}}\beta 4$ than $\alpha 3\beta 4$ nAChRs (Fig. 5A). Thus, the expectation was that it would also be a potent inhibitor of the ACh-evoked currents in human adrenal chromaffin cells since $\alpha 6\beta 4^*$ nAChRs were previously reported to be present (Perez-Alvarez et al., 2012b). However, substantial inhibition of the ACh-evoked current by PeIA(A7V,S9H,V10A,N11R,E14A) was only observed at 1 μM , a concentration >625-fold higher than the IC_{50} value for inhibition of $\alpha 6_{M211L,\alpha 3_{\text{cyt}}}\beta 4$ nAChRs expressed in oocytes (Fig. 5A). This coupled with the absence of significant inhibition by the LvIA analog suggests that the predominant nAChR subtype contains $\alpha 3$ - $\beta 4$ ligand-binding sites only.

In Pérez-Alvarez et al. (2012), evidence for the expression of $\alpha 6\beta 4^*$ nAChRs was based on the observation that α -Ctxs selective for rat $\alpha 6$ -containing nAChRs (Azam et al., 2008; McIntosh et al., 2004) inhibited the ACh-evoked currents in human adrenal chromaffin cells with similar IC_{50} values. Additionally, the IC_{50} value for the $\alpha 3\beta 4$ nAChR antagonist α -Ctx AuIB was estimated to be >10 μM which is inconsistent with the presence of a large population of $\alpha 3\beta 4$ nAChRs based on the IC_{50} value (750 nM) reported for rat $\alpha 3\beta 4$ nAChRs (Luo et al., 1998). We found that human $\alpha 3\beta 4$ nAChRs are relatively insensitive to inhibition by AuIB yet human $\alpha 6/\alpha 3\beta 4$ nAChRs are 20-fold more sensitive to inhibition (Fig. 9) than rat $\alpha 6/\alpha 3\beta 4$ nAChRs (Smith et al., 2013). The lack of human $\alpha 3\beta 4$ nAChR sensitivity to AuIB in oocytes is consistent with the results observed in human adrenal chromaffin cells and further supports our conclusion that these cells predominantly express $\alpha 3\beta 4^*$ nAChRs. Other α -Ctxs have also been found to be

MOL #100982

more potent on human $\beta 4$ -containing nAChRs than the rat homologs (Hernandez-Vivanco et al., 2014). In the present study, PeIA(A7V,S9H,V10A,N11R,E14A) was found to be ~27-fold more potent on human $\alpha 6_{M211L,cyt\alpha 3}\beta 4$ nAChRs (Fig. 5A) compared to the value reported for rat $\alpha 6\beta 4$ nAChRs (Hone et al., 2013). BuIA(T5A,P6O) is also more potent on both human $\alpha 3\beta 4$ and the $\alpha 6\beta 4$ nAChR constructs (Fig. 2) than the equivalent rat receptors (Azam et al., 2010). A comparison of the IC_{50} values for inhibition of rat and human $\alpha 3\beta 4$ and $\alpha 6\beta 4$ nAChRs by these α -Ctxs is presented in Table 5.

Species differences in the amino acid sequences of rat $\alpha 3$ and $\alpha 6$ subunits have been shown to influence α -Ctx on- and off-rate kinetics, potencies, and selectivity profiles (Azam et al., 2008; Hone et al., 2013). In the $\alpha 6$ subunit these differing residues include Glu¹⁵², Asp¹⁸⁴, and Thr¹⁹⁵ which in the $\alpha 3$ subunit are Lys, Glu, and Gln, respectively. Of these three residues, only Glu¹⁵² is conserved in the human $\alpha 3$ subunit while the other two residues at positions 184 and 195 are Asp and Pro, respectively (Fig. 8). Interestingly, human and rat $\alpha 6$ subunits also have an Asp at position 184 and thus, in this aspect, the human $\alpha 3$ subunit is more like rat $\alpha 6$ than rat $\alpha 3$. Similar observations have been made regarding the $\alpha 4$ subunit. α -Ctxs in general, including BuIA and its analogs, show very little activity on $\alpha 4$ -containing nAChRs. This lack of activity has been shown to be due to the presence of specific residues in the $\alpha 4$ ligand-binding pocket that are not present in other subtypes and that prevent efficient α -Ctx binding (Beissner et al., 2012; Everhart et al., 2003; Kim and McIntosh, 2012). These observations highlight the importance of continued work developing selective ligands that discriminate among the different human nAChR subtypes.

PCR experiments revealed that human medullary tissue and cultured human adrenal chromaffin cells predominantly express mRNA for the $\alpha 3$ subunit and express relatively low

MOL #100982

levels of mRNA for the $\alpha 6$ subunit (Figs. 6 and 7). Quantification of the transcripts in medullary tissue and cultured adrenal chromaffin cells by qPCR revealed that $\alpha 3$ transcripts are ~3.5 orders of magnitude more abundant than $\alpha 6$ transcripts (Figs. 6B and 7). Noteworthy, the concordance across tissue vs. cell culture and PCR methods was exceptionally high. Thus, together with the pharmacology experiments, converging lines of evidence strongly suggest that most heteromeric nAChRs in human chromaffin cells are of the $\alpha 3\beta 4^*$ subtype.

nAChRs composed of α and β subunits contain two putative ligand-binding sites composed of the primary site, contributed by the α subunit, and the complementary site, contributed by the β subunit. Hence, in a receptor composed of $\alpha 3$ and $\beta 4$ subunits, there are expected to be two pharmacologically similar ligand-binding sites. However, some receptor subtypes, such as those found on nigrostriatal dopaminergic terminals composed of $\alpha 4$, $\alpha 6$, and $\beta 2$ subunits contain two ligand-binding sites that are pharmacologically distinct (Gotti et al., 2005; Quik et al., 2005). This does not appear to be the case with the $\alpha 3\beta 4^*$ nAChRs in human adrenal chromaffin cells. We conclude that the $\alpha 3\beta 4^*$ nAChRs in these cells possess two $\alpha 3$ - $\beta 4$ ligand-binding interfaces. However, signals for both $\beta 2$ and $\alpha 5$ subunits were detected in PCR experiments (Fig. 6 and 7) suggesting that these subunits may be present in the $\alpha 3\beta 4^*$ nAChR complex. The $\alpha 5$ subunit has been detected in bovine adrenal chromaffin cells where it has been suggested to form $\alpha 3\beta 4\alpha 5$ nAChRs (Campos-Caro et al., 1997) and rat adrenal chromaffin cells have been reported to express $\alpha 3\beta 2$ nAChRs (Di Angelantonio et al., 2003). If $\beta 2$ subunits are present in human adrenal chromaffin cell $\alpha 3\beta 4^*$ nAChRs they are likely to be restricted to the 5th or auxiliary position since no pharmacological evidence for an $\alpha 3$ - $\beta 2$ ligand-binding site was found. Additionally, $\beta 2$ subunits may assemble with $\alpha 7$ subunits to form $\alpha 7\beta 2$ nAChRs which

MOL #100982

have recently been identified in rodent and human basal forebrain as well as mouse hippocampal interneurons (Liu et al., 2012; Liu et al., 2009b; Moretti et al., 2014).

In conclusion, this study describes the development of a novel pharmacological tool, LvIA(N9R,V10A), that can be used to selectively target human $\alpha 3\beta 2$ and $\alpha 6\beta 2$ nAChRs. We demonstrated its utility by using it in conjunction with a panel of α -Ctxs to characterize the nAChR subtypes expressed by a cell that was thought to potentially express multiple subtypes. Data from previous studies suggested that human adrenal chromaffin cells may express both $\alpha 3\beta 4$ and $\alpha 6\beta 4$ nAChRs as well as subtypes with $\beta 2$ ligand-binding sites (Perez-Alvarez et al., 2012b). Here we present evidence that human adrenal chromaffin cells in fact predominantly express nAChRs with only $\alpha 3$ - $\beta 4$ ligand-binding sites. Thus, these studies not only clarify the nAChR expression in human adrenal chromaffin cells but also suggest that the stoichiometry of the predominant nAChR is likely $(\alpha 3\beta 4)_2$ with an auxiliary 5th subunit that is yet to be identified. Future experiments are clearly warranted to identify this 5th subunit since auxiliary subunits can play an important role in determining agonist sensitivity and calcium permeability (Brown et al., 2007; Gerzanich et al., 1998; Sciacaluga et al., 2015). Combined approaches using selective immunoprecipitation, radioligand binding, and immunohistochemistry may be particularly helpful in this regard (Gotti et al., 2005; Grady et al., 2009; Lomazzo et al., 2010; Marks et al., 2011; Whiteaker et al., 2000).

MOL #100982

Acknowledgements.

We thank Bob Shackman at the DNA/Peptide Synthesis core facility (University of Utah), Joanna Gajewiak (University of Utah) for assistance with peptide synthesis, Sean Christensen (University of Utah) for assistance with the peptide folding, and William Lowe at the Salk Institute for performing the MALDI mass spectrometry.

MOL #100982

Author contributions.

Participated in Research Design: Hone, McIntosh, Albillos

Conducted experiments: Hone, Azam, Lucero

Performed data analysis: Hone, Lucero

Contributed Reagents: Lindstrom, Whiteaker, Passas, Blázquez

Contributed to the writing of the manuscript: Hone, McIntosh, Lucero, Whiteaker, Albillos

MOL #100982

References

- Albuquerque EX, Pereira EF, Alkondon M and Rogers SW (2009) Mammalian nicotinic acetylcholine receptors: from structure to function. *Physiol Rev* **89**(1):73-120.
- Andersen CL, Jensen JL and Orntoft TF (2004) Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. *Cancer Res* **64**(15):5245-5250.
- Azam L, Maskos U, Changeux JP, Dowell CD, Christensen S, De Biasi M and McIntosh JM (2010) alpha-Conotoxin BuIA[T5A;P6O]: a novel ligand that discriminates between alpha6beta4 and alpha6beta2 nicotinic acetylcholine receptors and blocks nicotine-stimulated norepinephrine release. *FASEB J* **24**(12):5113-5123.
- Azam L and McIntosh JM (2006) Characterization of nicotinic acetylcholine receptors that modulate nicotine-evoked [³H]norepinephrine release from mouse hippocampal synaptosomes. *Mol Pharmacol* **70**(3):967-976.
- Azam L, Yoshikami D and McIntosh JM (2008) Amino acid residues that confer high selectivity of the alpha6 nicotinic acetylcholine receptor subunit to alpha-conotoxin MII[S4A,E11A,L15A]. *J Biol Chem* **283**(17):11625-11632.
- Beissner M, Dutertre S, Schemm R, Danker T, Sporning A, Grubmuller H and Nicke A (2012) Efficient binding of 4/7 alpha-conotoxins to nicotinic alpha4beta2 receptors is prevented by Arg185 and Pro195 in the alpha4 subunit. *Mol Pharmacol* **82**(4):711-718.
- Brown RW, Collins AC, Lindstrom JM and Whiteaker P (2007) Nicotinic alpha5 subunit deletion locally reduces high-affinity agonist activation without altering nicotinic receptor numbers. *J Neurochem* **103**(1):204-215.
- Campos-Caro A, Smillie FI, Dominguez del Toro E, Rovira JC, Vicente-Agullo F, Chapuli J, Juiz JM, Sala S, Sala F, Ballesta JJ and Criado M (1997) Neuronal nicotinic acetylcholine receptors on bovine chromaffin cells: cloning, expression, and genomic organization of receptor subunits. *J Neurochem* **68**(2):488-497.
- Carlisle DL, Hopkins TM, Gaither-Davis A, Silhanek MJ, Luketich JD, Christie NA and Siegfried JM (2004) Nicotine signals through muscle-type and neuronal nicotinic acetylcholine receptors in both human bronchial epithelial cells and airway fibroblasts. *Respir Res* **5**:27.
- Cartier GE, Yoshikami D, Gray WR, Luo S, Olivera BM and McIntosh JM (1996) A new alpha-conotoxin which targets alpha3beta2 nicotinic acetylcholine receptors. *J Biol Chem* **271**(13):7522-7528.
- Criado M, Dominguez del Toro E, Carrasco-Serrano C, Smillie FI, Juiz JM, Viniegra S and Ballesta JJ (1997) Differential expression of alpha-bungarotoxin-sensitive neuronal nicotinic receptors in adrenergic chromaffin cells: a role for transcription factor Egr-1. *J Neurosci* **17**(17):6554-6564.
- Di Angelantonio S, Matteoni C, Fabbretti E and Nistri A (2003) Molecular biology and electrophysiology of neuronal nicotinic receptors of rat chromaffin cells. *Eur J Neurosci* **17**(11):2313-2322.
- Everhart D, Reiller E, Mirzoian A, McIntosh JM, Malhotra A and Luetje CW (2003) Identification of residues that confer alpha-conotoxin-PnIA sensitivity on the alpha 3 subunit of neuronal nicotinic acetylcholine receptors. *J Pharmacol Exp Ther* **306**(2):664-670.

MOL #100982

- Gahring LC, Myers E, Palumbos S and Rogers SW (2014) Nicotinic receptor Alpha7 expression during mouse adrenal gland development. *PLoS One* **9**(8):e103861.
- George AA, Lucero LM, Damaj MI, Lukas RJ, Chen X and Whiteaker P (2012) Function of human alpha3beta4alpha5 nicotinic acetylcholine receptors is reduced by the alpha5(D398N) variant. *J Biol Chem* **287**(30):25151-25162.
- Gerzanich V, Wang F, Kuryatov A and Lindstrom J (1998) alpha 5 Subunit alters desensitization, pharmacology, Ca⁺⁺ permeability and Ca⁺⁺ modulation of human neuronal alpha 3 nicotinic receptors. *J Pharmacol Exp Ther* **286**(1):311-320.
- Gotti C, Moretti M, Clementi F, Riganti L, McIntosh JM, Collins AC, Marks MJ and Whiteaker P (2005) Expression of nigrostriatal alpha 6-containing nicotinic acetylcholine receptors is selectively reduced, but not eliminated, by beta 3 subunit gene deletion. *Mol Pharmacol* **67**(6):2007-2015.
- Grady SR, Moretti M, Zoli M, Marks MJ, Zanardi A, Pucci L, Clementi F and Gotti C (2009) Rodent habenulo-interpeduncular pathway expresses a large variety of uncommon nAChR subtypes, but only the alpha3beta4* and alpha3beta3beta4* subtypes mediate acetylcholine release. *J Neurosci* **29**(7):2272-2282.
- Groebe DR, Dumm JM, Levitan ES and Abramson SN (1995) alpha-Conotoxins selectively inhibit one of the two acetylcholine binding sites of nicotinic receptors. *Mol Pharmacol* **48**(1):105-111.
- Hernandez-Vivanco A, Hone AJ, Scadden ML, Carmona-Hidalgo B, McIntosh JM and Albillos A (2014) Monkey adrenal chromaffin cells express alpha6beta4* nicotinic acetylcholine receptors. *PLoS One* **9**(4):e94142.
- Hone AJ, Meyer EL, McIntyre M and McIntosh JM (2012a) Nicotinic acetylcholine receptors in dorsal root ganglion neurons include the alpha6beta4* subtype. *FASEB J* **26**(2):917-926.
- Hone AJ, Ruiz M, Scadden M, Christensen S, Gajewiak J, Azam L and McIntosh JM (2013) Positional scanning mutagenesis of alpha-conotoxin PeIA identifies critical residues that confer potency and selectivity for alpha6/alpha3beta2beta3 and alpha3beta2 nicotinic acetylcholine receptors. *J Biol Chem* **288**(35):25428-25439.
- Hone AJ, Scadden M, Gajewiak J, Christensen S, Lindstrom J and McIntosh JM (2012b) alpha-Conotoxin PeIA[S9H,V10A,E14N] potently and selectively blocks alpha6beta2beta3 versus alpha6beta4 nicotinic acetylcholine receptors. *Mol Pharmacol* **82**(5):972-982.
- Hone AJ, Whiteaker P, Christensen S, Xiao Y, Meyer EL and McIntosh JM (2009) A novel fluorescent alpha-conotoxin for the study of alpha7 nicotinic acetylcholine receptors. *J Neurochem* **111**(1):80-89.
- Innocent N, Livingstone PD, Hone A, Kimura A, Young T, Whiteaker P, McIntosh JM and Wonnacott S (2008) Alpha-conotoxin Arenatus IB[V11L,V16D] [corrected] is a potent and selective antagonist at rat and human native alpha7 nicotinic acetylcholine receptors. *J Pharmacol Exp Ther* **327**(2):529-537.
- Jacobsen RB, Delacruz RG, Grose JH, McIntosh JM, Yoshikami D and Olivera BM (1999) Critical residues influence the affinity and selectivity of alpha-conotoxin MI for nicotinic acetylcholine receptors. *Biochemistry* **38**(40):13310-13315.
- Kim HW and McIntosh JM (2012) alpha6 nAChR subunit residues that confer alpha-conotoxin BuIA selectivity. *FASEB J* **26**(10):4102-4110.
- Kuryatov A and Lindstrom J (2011) Expression of functional human alpha6beta2beta3* acetylcholine receptors in *Xenopus laevis* oocytes achieved through subunit chimeras and concatamers. *Mol Pharmacol* **79**(1):126-140.

MOL #100982

- Kuryatov A, Olale F, Cooper J, Choi C and Lindstrom J (2000) Human alpha6 AChR subtypes: subunit composition, assembly, and pharmacological responses. *Neuropharmacology* **39**(13):2570-2590.
- Kurzen H, Berger H, Jager C, Hartschuh W, Naher H, Gratchev A, Goerdts S and Deichmann M (2004) Phenotypical and molecular profiling of the extraneuronal cholinergic system of the skin. *J Invest Dermatol* **123**(5):937-949.
- Ley CK, Kuryatov A, Wang J and Lindstrom JM (2014) Efficient expression of functional (alpha6beta2)2beta3 AChRs in *Xenopus* oocytes from free subunits using slightly modified alpha6 subunits. *PLoS One* **9**(7):e103244.
- Lips KS, Bruggmann D, Pfeil U, Vollerthun R, Grando SA and Kummer W (2005) Nicotinic acetylcholine receptors in rat and human placenta. *Placenta* **26**(10):735-746.
- Liu J, McGlenn AM, Fernandes A, Milam AH, Strang CE, Anderson ME, Lindstrom JM, Keyser KT and Stone RA (2009a) Nicotinic acetylcholine receptor subunits in rhesus monkey retina. *Invest Ophthalmol Vis Sci* **50**(3):1408-1415.
- Liu Q, Huang Y, Shen J, Steffensen S and Wu J (2012) Functional alpha7beta2 nicotinic acetylcholine receptors expressed in hippocampal interneurons exhibit high sensitivity to pathological level of amyloid beta peptides. *BMC Neurosci* **13**:155.
- Liu Q, Huang Y, Xue F, Simard A, DeChon J, Li G, Zhang J, Lucero L, Wang M, Sierks M, Hu G, Chang Y, Lukas RJ and Wu J (2009b) A novel nicotinic acetylcholine receptor subtype in basal forebrain cholinergic neurons with high sensitivity to amyloid peptides. *J Neurosci* **29**(4):918-929.
- Livak KJ and Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2^{-Delta Delta C(T)} Method. *Methods* **25**(4):402-408.
- Lomazzo E, MacArthur L, Yasuda RP, Wolfe BB and Kellar KJ (2010) Quantitative analysis of the heteromeric neuronal nicotinic receptors in the rat hippocampus. *J Neurochem* **115**(3):625-634.
- Luo S, Kulak JM, Cartier GE, Jacobsen RB, Yoshikami D, Olivera BM and McIntosh JM (1998) alpha-conotoxin AuIB selectively blocks alpha3 beta4 nicotinic acetylcholine receptors and nicotine-evoked norepinephrine release. *J Neurosci* **18**(21):8571-8579.
- Luo S, Nguyen TA, Cartier GE, Olivera BM, Yoshikami D and McIntosh JM (1999) Single-residue alteration in alpha-conotoxin PnIA switches its nAChR subtype selectivity. *Biochemistry* **38**(44):14542-14548.
- Luo S, Zhangsun D, Schroeder CI, Zhu X, Hu Y, Wu Y, Weltzin MM, Eberhard S, Kaas Q, Craik DJ, McIntosh JM and Whiteaker P (2014) A novel alpha4/7-conotoxin LvIA from *Conus lividus* that selectively blocks alpha3beta2 vs. alpha6/alpha3beta2beta3 nicotinic acetylcholine receptors. *FASEB J* **28**(4):1842-1853.
- Luo S, Zhangsun D, Wu Y, Zhu X, Hu Y, McIntyre M, Christensen S, Akcan M, Craik DJ and McIntosh JM (2013) Characterization of a novel alpha-conotoxin from *Conus textile* that selectively targets alpha6/alpha3beta2beta3 nicotinic acetylcholine receptors. *J Biol Chem* **288**(2):894-902.
- Marks MJ, McClure-Begley TD, Whiteaker P, Salminen O, Brown RW, Cooper J, Collins AC and Lindstrom JM (2011) Increased nicotinic acetylcholine receptor protein underlies chronic nicotine-induced up-regulation of nicotinic agonist binding sites in mouse brain. *J Pharmacol Exp Ther* **337**(1):187-200.

MOL #100982

- McIntosh JM, Azam L, Staheli S, Dowell C, Lindstrom JM, Kuryatov A, Garrett JE, Marks MJ and Whiteaker P (2004) Analogs of alpha-conotoxin MII are selective for alpha6-containing nicotinic acetylcholine receptors. *Mol Pharmacol* **65**(4):944-952.
- Mikulski Z, Hartmann P, Jositsch G, Zaslona Z, Lips KS, Pfeil U, Kurzen H, Lohmeyer J, Clauss WG, Grau V, Fronius M and Kummer W (2010) Nicotinic receptors on rat alveolar macrophages dampen ATP-induced increase in cytosolic calcium concentration. *Respir Res* **11**:133.
- Mollard P, Seward EP and Nowycky MC (1995) Activation of nicotinic receptors triggers exocytosis from bovine chromaffin cells in the absence of membrane depolarization. *Proc Natl Acad Sci U S A* **92**(7):3065-3069.
- Moretti M, Zoli M, George AA, Lukas RJ, Pistillo F, Maskos U, Whiteaker P and Gotti C (2014) The novel alpha7beta2-nicotinic acetylcholine receptor subtype is expressed in mouse and human basal forebrain: biochemical and pharmacological characterization. *Mol Pharmacol* **86**(3):306-317.
- Peng H, Ferris RL, Matthews T, Hiel H, Lopez-Albaitero A and Lustig LR (2004) Characterization of the human nicotinic acetylcholine receptor subunit alpha (alpha) 9 (CHRNA9) and alpha (alpha) 10 (CHRNA10) in lymphocytes. *Life Sci* **76**(3):263-280.
- Perez-Alvarez A, Hernandez-Vivanco A, Gregorio SA, Tabernero A, McIntosh JM and Albillos A (2012a) Pharmacological characterization of native alpha7 nAChRs and their contribution to depolarization-elicited exocytosis in human chromaffin cells. *Br J Pharmacol* **165**(4):908-921.
- Perez-Alvarez A, Hernandez-Vivanco A, McIntosh JM and Albillos A (2012b) Native alpha6beta4* nicotinic receptors control exocytosis in human chromaffin cells of the adrenal gland. *FASEB J* **26**(1):346-354.
- Pfaffl MW, Tichopad A, Prgomet C and Neuvians TP (2004) Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper--Excel-based tool using pair-wise correlations. *Biotechnol Lett* **26**(6):509-515.
- Quik M, Vailati S, Bordia T, Kulak JM, Fan H, McIntosh JM, Clementi F and Gotti C (2005) Subunit composition of nicotinic receptors in monkey striatum: effect of treatments with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine or L-DOPA. *Mol Pharmacol* **67**(1):32-41.
- Sciaccaluga M, Moriconi C, Martinello K, Catalano M, Bermudez I, Stitzel JA, Maskos U and Fucile S (2015) Crucial role of nicotinic alpha5 subunit variants for Ca²⁺ fluxes in ventral midbrain neurons. *FASEB J*.
- Silver N, Best S, Jiang J and Thein SL (2006) Selection of housekeeping genes for gene expression studies in human reticulocytes using real-time PCR. *BMC Mol Biol* **7**:33.
- Sine SM, Kreienkamp HJ, Bren N, Maeda R and Taylor P (1995) Molecular dissection of subunit interfaces in the acetylcholine receptor: identification of determinants of alpha-conotoxin M1 selectivity. *Neuron* **15**(1):205-211.
- Smith NJ, Hone AJ, Memon T, Bossi S, Smith TE, McIntosh JM, Olivera BM and Teichert RW (2013) Comparative functional expression of nAChR subtypes in rodent DRG neurons. *Frontiers in cellular neuroscience* **7**:225.
- Talley TT, Olivera BM, Han KH, Christensen SB, Dowell C, Tsigelny I, Ho KY, Taylor P and McIntosh JM (2006) Alpha-conotoxin OmIA is a potent ligand for the acetylcholine-binding protein as well as alpha3beta2 and alpha7 nicotinic acetylcholine receptors. *J Biol Chem* **281**(34):24678-24686.

MOL #100982

- Teichert RW, Rivier J, Torres J, Dykert J, Miller C and Olivera BM (2005) A uniquely selective inhibitor of the mammalian fetal neuromuscular nicotinic acetylcholine receptor. *J Neurosci* **25**(3):732-736.
- Turner JR and Kellar KJ (2005) Nicotinic cholinergic receptors in the rat cerebellum: multiple heteromeric subtypes. *J Neurosci* **25**(40):9258-9265.
- Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A and Speleman F (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. *Genome Biol* **3**(7):RESEARCH0034.
- West KA, Brognard J, Clark AS, Linnoila IR, Yang X, Swain SM, Harris C, Belinsky S and Dennis PA (2003) Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. *J Clin Invest* **111**(1):81-90.
- Whiteaker P, Christensen S, Yoshikami D, Dowell C, Watkins M, Gulyas J, Rivier J, Olivera BM and McIntosh JM (2007) Discovery, synthesis, and structure activity of a highly selective alpha7 nicotinic acetylcholine receptor antagonist. *Biochemistry* **46**(22):6628-6638.
- Whiteaker P, Jimenez M, McIntosh JM, Collins AC and Marks MJ (2000) Identification of a novel nicotinic binding site in mouse brain using [(125)I]-epibatidine. *Br J Pharmacol* **131**(4):729-739.
- Whiteaker P, Wilking JA, Brown RW, Brennan RJ, Collins AC, Lindstrom JM and Boulter J (2009) Pharmacological and immunochemical characterization of alpha2* nicotinic acetylcholine receptors (nAChRs) in mouse brain. *Acta Pharmacol Sin* **30**(6):795-804.

MOL #100982

Footnotes.

A.J.H holds a Marie Curie International Fellowship from the European Commission [NRHACC-329966]. This work was also supported by grants from the Spanish Ministerio de Ciencia y Tecnología [BFU2012-30997] to A.A., the U.S. National Institutes of Health [GM-103801 and GM-48677] to J.M.M, [DA030929] to J.L, [R21 DA026627, R21 DA027070S and R01 DA012242] to PW and by funds provided to PW by the Barrow Neurological Foundation.

MOL #100982

Figure Legends.

Fig. 1. Pharmacological profile of LvIA(N9R,V10A) for inhibition of human nAChRs expressed in *Xenopus* oocytes. Oocytes expressing different nAChR subtypes were subjected to TEVC electrophysiology as described in *Materials and Methods*. LvIA(N9R,V10A) inhibited $\alpha 3\beta 2$, $\alpha 6/\alpha 3\beta 2\beta 3$, and $\beta 3\alpha 6\beta 2\alpha 4\beta 2$ nAChRs with IC_{50} values of 3.3 (2.4-4.7) nM (n=4), 13.5 (8.6-21.2) nM (n=3), and 11.4 (8.1-16.0) nM (n=4), respectively. The $\alpha 6/\alpha 3\beta 4$ and $\alpha 6_{M211L,cyt\alpha 3}\beta 4$ constructs were inhibited with IC_{50} values of 1.0 (0.8-1.3) μ M (n=4) and 2.8 (2.5-3.4) μ M respectively. The peptide also inhibited $\alpha 4\beta 2$ nAChRs with an IC_{50} of 195 (133-284) nM (n=4). For $\alpha 3\beta 4$, $\beta 4\alpha 3\beta 4\alpha 3\alpha 5(D)$, and $\alpha 4\beta 4$ nAChRs the average response after a 5 min static bath exposure to 10 μ M LvIA(N9R,V10A) was $88 \pm 4\%$ (n=4) and $97 \pm 1\%$ (n=4), respectively. The error bars denote the S.E.M. and the values in parenthesis denote the 95% confidence interval.

Fig. 2. Pharmacological profile of α -Ctx BuIA(T5A,P6O) for inhibition of human nAChRs expressed in *Xenopus* oocytes. Oocytes expressing different nAChR subtypes were subjected to TEVC electrophysiology as described in *Materials and Methods*. BuIA(T5A,P6O) inhibited $\alpha 6/\alpha 3\beta 4$ nAChRs with an IC_{50} of 7.4 (6.5-8.3) nM (n=4), $\alpha 6_{M211L,cyt\alpha 3}\beta 4$ with an IC_{50} of 11.3 (10.1-12.7) nM (n=4), $\alpha 3\beta 4$ nAChRs with an IC_{50} of 166 (141-196) nM (n=4), and $\beta 4\alpha 3\beta 4\alpha 5(D)$ with an IC_{50} of 147 (127-171) nM (n=3). For other subtypes, the average response after a 5 min static bath exposure to 10 μ M BuIA(T5A,P6O) was $96 \pm 4\%$ (n=4) for $\alpha 3\beta 2$, $95 \pm 5\%$ (n=4) for $\alpha 4\beta 2$, $48 \pm 4\%$ (n=3) for $\alpha 4\beta 4$, $77 \pm 3\%$ (n=4) for $\alpha 6/\alpha 3\beta 2\beta 3$, and $101 \pm 2\%$ (n=4) for $\beta 3\alpha 6\beta 2\alpha 4\beta 2$. The error bars denote the S.E.M. and the values in parenthesis denote the 95% confidence interval. For clarity, data for $\alpha 3\beta 4$ and $\beta 3\alpha 6\beta 2\alpha 4\beta 2$ have been nudged to the right to avoid overlap.

MOL #100982

Fig. 3. Human non $\alpha 7$ nAChRs are insensitive to α -Ctx ArIB(V11L,V16D). The indicated nAChR subtypes were expressed in *Xenopus laevis* oocytes and subjected to TEVC as described in *Materials and Methods*. Current traces showing the inhibition of ACh-evoked currents after a 5 min static bath exposure to 10 μ M α -Ctx. The average responses for $\alpha 3\beta 2$, $\alpha 3\beta 4$, $\beta 3\alpha 6\beta 2\alpha 4\beta 2$, and $\alpha 6_{M211L,cyt\alpha 3}\beta 4$ were $93 \pm 2\%$ (n=4), $95 \pm 3\%$ (n=4), $91 \pm 11\%$ (n=3), and $88 \pm 2\%$ (n=4), respectively. Values are the S.E.M.; C, control response to 300 μ M ACh prior to application of ArIB(V11L,V16D).

Fig. 4. α -Ctx BuIA(T5A,P6O), but not LvIA(N9R,V10A), potently inhibits ACh-evoked currents in human adrenal chromaffin cells. Chromaffin cells were isolated from human adrenal glands and subjected to perforated patch-clamp electrophysiology as described in *Materials and Methods*. (A) BuIA(T5A,P6O) inhibited ACh-evoked currents with an IC_{50} of 46.8 (39.8-55.1) nM (n=7); the Hill slope was -0.98 (0.85-1.1). LvIA(N9R,V10A) inhibited ACh-evoked currents with an IC_{50} value $>1 \mu$ M (n=4). The error bars denote the S.E.M. and the values in parenthesis denote the 95% confidence intervals. (B) Representative traces for the inhibition of ACh-evoked currents by increasing concentrations of BuIA(T5A,P6O) and (C) LvIA(N9R,V10A). (D, E) Representative traces showing the inhibition of ACh-evoked currents by both α -Ctxs when tested in the same cell. The LvIA analog inhibited ACh-evoked currents by $8.5 \pm 6\%$ (n=6) and after washout the BuIA analog inhibited the currents by $98 \pm 0.7\%$ (n=6). Values are S.E.M. In D and E, the LvIA and BuIA analogs are denoted with an asterisk for brevity. Control responses to ACh in the absence of α -Ctxs are shown in red.

MOL #100982

Fig. 5. α -Ctx PeIA(A7V,S9H,V10A,N11R,E14A) is selective for human $\alpha_{6M211L,cyt\alpha3}\beta_4$ over $\alpha_3\beta_4$ nAChRs expressed in *Xenopus* oocytes and identifies the $\alpha_3\beta_4^*$ subtype as the main nAChR subtype expressed by human adrenal chromaffin cells. Oocytes expressing different nAChR subtypes were subjected to TEVC electrophysiology as described in *Materials and Methods*. (A), PeIA(A7V,S9H,V10A,N11R,E14A) inhibited $\alpha_{6M211L,cyt\alpha3}\beta_4$ nAChRs with an IC_{50} of 1.6 (1.1-2.2) nM (n=4), $\alpha_6/\alpha_3\beta_2\beta_3$ with an IC_{50} of 3.8 (3.2-4.5) nM (n=4), and $\beta_3\alpha_6\beta_2\alpha_4\beta_2$ with an IC_{50} of 6.3 (5.6-7.1) nM (n=4). The $\alpha_3\beta_2$, $\alpha_3\beta_4$ and $\beta_4\alpha_3\beta_4\alpha_3\alpha_5(D)$ subtypes were inhibited with IC_{50} values of 6.1 (3.6-10.3) μ M, 4.7 (3.5-6.2) μ M, and 9.2 (6.1-13.4) μ M, respectively (n=4 for all). For $\alpha_4\beta_2$ and $\alpha_4\beta_4$, the average responses after a 5 min static bath exposure to 10 μ M peptide were $85 \pm 2\%$ (n=4) and $79 \pm 5\%$ (n=4), respectively. (A) Human adrenal chromaffin cells were subjected to patch-clamp electrophysiology as described in *Materials and Methods*. The cells were perfused with increasing concentrations of the PeIA analog and the ACh-evoked currents monitored for inhibition. The IC_{50} value for inhibition of these currents was estimated to be greater than the maximal concentration tested (1 μ M) (n=6). (B) Oocytes expressing $\alpha_3\beta_4$ or $\alpha_{6M211L,cyt\alpha3}\beta_4$ nAChRs were perfused with 1 μ M and 3 nM PeIA(A7V,S9H,V10A,N11R,E14A), respectively, until steady state inhibition was observed and then perfused with ND96 only and the responses monitored for recovery. Complete inhibition equilibrium of $\alpha_3\beta_4$ nAChRs was obtained in ~ 1 and complete recovery occurred in < 2 min. In contrast, steady state inhibition of $\alpha_{6M211L,cyt\alpha3}\beta_4$ required ~ 15 min and recovery from inhibition required > 15 min. The error bars denote the S.E.M. and the values in parenthesis denote the 95% confidence interval; ACC, human adrenal chromaffin cells.

Fig. 6. PCR analysis of human adrenal medulla tissue demonstrates the presence of mRNAs for multiple nAChR subunits. (A) Strong signals for nAChR subunit transcripts were detected for

MOL #100982

α 3, α 5, α 7, β 2, and β 4 subunits and relatively weak signals for α 2, α 4, α 6, and α 10 subunits. Transcripts for α 9 and β 3 were not detected under the conditions used in this study. Negative control results for reactions performed in the absence of cDNA template are shown in the lane immediately to the right of each respective subunit. Equal volumes of all reactions were loaded on the gel. The molecular weight ladder is shown and denotes size of the amplicon in numbers of base pairs (100 bp increments). Expected sizes for each amplicon are listed in Table 3. The data shown were obtained from 1 adrenal medulla (n=3). (B) qPCR analysis quantitatively confirmed and extended the results presented in (A). Transcripts for α 3, α 7, and β 4 were the three most abundant mRNA species present followed by α 5 and β 2. Transcripts for α 2, α 6, and α 10 were weakly detected while those for α 4, α 9, and β 3 were infrequently detected (data not shown). Transcripts for α 3 were on average 3.4 ± 0.2 (n=4) orders of magnitude more abundant than α 6. Data were normalized to the expression levels of reference genes using the $\log_{10}(2^{-\Delta Cq})$ method as described in *Material and Methods*. (C) Comparison of the relative abundance of mRNA transcripts in adrenal medulla with human brain. Transcripts for α 3 were more abundant than those for α 6 in adrenal medulla while in brain tissue, α 6 was the more abundant species. Data were normalized to the expression levels in human brain using the $\log_{10}(2^{-\Delta\Delta Cq})$ method as described in *Material and Methods*. In B and C, the error bars represent the SEM of 4 experiments using adrenal glands from 4 individual donors. Statistical significance was determined using an ANOVA and Bonferroni test (***) $p < 0.001$).

Fig. 7. qPCR analysis of cultured human adrenal chromaffin cells. Transcripts for α 3, α 7, and β 4 were the three most highly abundant mRNA species present in cultured adrenal chromaffin cells followed by α 5 and β 2. Transcripts for α 2, α 6, and α 10 were weakly detected while those for α 4, α 9, and β 3 were infrequently detected (data not shown). Transcripts for α 3 were on

MOL #100982

average 3.5 ± 0.5 (n=3) orders of magnitude more abundant than $\alpha 6$. Data were normalized to the expression levels of reference genes using the $\log_{10}(2^{-\Delta Cq})$ method as described in *Material and Methods*. The error bars represent the SEM of 3 experiments using cell cultures of adrenal glands from 3 individual donors. Statistical significance was determined using an ANOVA and Bonferroni test ($***p < 0.001$).

Fig. 8. Residues in the ligand-binding domains of rat and human $\alpha 3$ and $\alpha 6$ subunits are only partially conserved between the two species. A sequence comparison of amino acids 150 through 200 of rat and human $\alpha 3$ and $\alpha 6$ ligand-binding domains was performed. Residues marked with the asterisk and numbered 152, 184, and 195 are important for α -Ctx binding. Note that residue 152 is conserved between rat and human $\alpha 3$ subunits but not residues 184 and 195.

Fig. 9. α -Ctx AuIB inhibits human $\alpha 6/\alpha 3\beta 4$ nAChRs more potently than $\alpha 3\beta 4$ nAChRs. Oocytes expressing $\alpha 6/\alpha 3\beta 4$ or $\alpha 3\beta 4$ nAChR subtypes were subjected to TEVC electrophysiology as described in *Materials and Methods*. AuIB inhibited $\alpha 6/\alpha 3\beta 4$ nAChRs with an IC_{50} value of 360 (305-424) nM (n=4) and $\alpha 3\beta 4$ nAChRs with an IC_{50} value $> 10 \mu M$ (n=4). The error bars denote the S.E.M. and the values in parenthesis denote the 95% confidence interval

MOL #100982

Tables.

TABLE 1

Sequence comparison of select α -Ctxs and their selectivity profiles

	Amino Acid Sequence	nAChR Potency	Reference
<u>α-Conotoxin</u>			
LvIA	GCCSHPACNVDHPEIC	$\alpha3\beta2 > \alpha3\beta4$; $\alpha6/\alpha3\beta2\beta3 = \alpha6/\alpha3\beta4$	(Luo et al., 2014)
TxIB	GCCSDPPCRNKHPDLC	$\alpha6/\alpha3\beta2\beta3 >> \alpha3\beta2, \alpha3\beta4, \alpha6/\alpha3\beta4$	(Luo et al., 2013)
PnIA	GCCSLPPCAANNPDYC	$\alpha3\beta2 >> \alpha3\beta4$; $\alpha6/\alpha3\beta2\beta3 > \alpha6/\alpha3\beta4$	(Luo et al., 1999)
LvIA(N9R, V10A)	GCCSHPACRADHPEIC	$\alpha3\beta2 >>> \alpha3\beta4$; $\alpha6/\alpha3\beta2\beta3 >> \alpha6/\alpha3\beta4$	<i>This work</i>

>, 2-99-fold; >>, 100-500-fold; >>>, >1000-fold.

Residues shaded are conserved between the four peptides and residues bolded are those substituted from TxIB and PnIA.

MOL #100982

TABLE 2

IC₅₀ values for inhibition of human nAChRs expressed in *Xenopus* oocytes and adrenal chromaffin cells nAChRs

	BuIA(T5A,P6O)	LvIA(N9R,V10A)	PeIA(A7V,S9H,V10A,N11R,E14A)
$\alpha 3\beta 2$	>10 μ M	3.3 (2.4-4.7) nM	6.1 (3.6-10.3) μ M
$\alpha 3\beta 4$	166 (141-196) nM	>10 μ M	3.7 (2.4-5.8) μ M
$\beta 4\alpha 3\beta 4\alpha 3\alpha 5(D)$	147 (125-173) nM	>10 μ M	9.2 (6.4-13.4) μ M
$\alpha 4\beta 2$	>10 μ M	195 (133-284) nM	>10 μ M
$\alpha 4\beta 4$	>10 μ M	>10 μ M	>10 μ M
$\alpha 6/\alpha 3\beta 2\beta 3$	>10 μ M	13.5 (8.6-21.2) nM	3.8 (3.2-4.5) nM
$\beta 3\alpha 6\beta 2\alpha 4\beta 2$	>10 μ M	11.4 (8.1-16.0) nM	6.3 (5.6-7.1) nM
$\alpha 6/\alpha 3\beta 4$	7.4 nM (6.5-8.3) nM	1.0 (7.5-13.3) μ M	ND
$\alpha 6_{M211L,cyt\alpha 3}\beta 4$	11.3 (10.1-12.7) nM	2.8 (2.5-3.3) μ M	1.6 (1.2-2.2) nM
ACC	46.7 (39.8-55.1) nM	>1 μ M	>1 μ M

Values in parenthesis indicate the 95% confidence interval.

ACC, adrenal chromaffin cells.

ND, not determined.

MOL #100982

Table 3

Primers for nAChR subunit mRNA, amplicon size, and annealing temperature used in PCR.

Target	Primer Sequence	Size	Temp.	Reference
$\alpha 2$	5'-CCGGTGGCTTCTGATGA-3' (s)	466 bp	55 °C	(West et al., 2003)
	5'-CAGATCATTCCAGCTAGG-3' (as)			
$\alpha 3$	5'-CCATGTCTCAGCTGGTG-3' (s)	401 bp	55 °C	(West et al., 2003)
	5'-GTCCTTGAGGTTTCATGGA-3' (as)			
$\alpha 4$	5'-GGATGAGAAGAACCAGATGA-3' (s)	444 bp	58 °C	(Carlisle et al., 2004)
	5'-CTCGTACTTCCTGGTGTGT-3' (as)			
$\alpha 5$	5'-GGCCTCTGGACAAGACAA-3' (s)	179 bp	60 °C	(Liu et al., 2009a)
	5'-AAGATTTTCCTGTGTTCCC-3' (as)			
$\alpha 6$	5'-TCCATCGTGGTGACTGTGT-3' (s)	413 bp	55 °C	(West et al., 2003)
	5'-AGGCCACCTCATCAGCAG-3' (as)			
$\alpha 7$	5'-CTTCACCATCATCTGCACCATC-3' (s)	308 bp	58 °C	(Kurzen et al., 2004)
	5'-GGTACGGATGTGCCAAGGATAT-3' (as)			
$\alpha 9$	5'-GTCCAGGGTCTTGTGTTGT-3' (s)	403 bp	55 °C	(West et al., 2003)
	5'-ATCCGCTCTTGCTATGAT-3' (as)			
$\alpha 10$	5'-CTGTTCCGTGACCTCTTCG-3' (s)	388 bp	60 °C	(West et al., 2003)
	5'-GAAGGCCGCCACGTCCA-3' (as)			
$\beta 2$	5'-CAGCTCATCAGTGTGCA-3' (s)	347 bp	55 °C	(West et al., 2003)
	5'-GTGCGGTCGTAGGTCCA-3' (as)			
$\beta 3$	5'-TGGAGAGTACCTGCTGTTCA-3' (s)	439 bp	58 °C	(Carlisle et al., 2004)
	5'-CGAGCCTGTTACTGACACTA-3' (as)			
$\beta 4$	5'-AGCAAGTCATGCGTGACCAAG-3' (s)	210 bp	60 °C	(Liu et al., 2009a)
	5'-GCTGACACCTTCTAATGCCTCC-3' (as)			

MOL #100982

Table 4

TaqMan qPCR assay

Assay ID	Context Sequence	Gene symbol	Accession Number
Hs00181237_m1	CTCTACAACAATGCAGATGGGGAGT	CHRNA2	NM_000742.3
Hs01088199_m1	ACCTGTGGCTCAAGCAAATCTGGAA	CHRNA3	NM_001166694.1
Hs00181247_m1	ACACAGACTTCTCGGTGAAGGAGGA	CHRNA4	NM_001256573.1
Hs00181248_m1	AATTGGTGGATGTGGATGAGAAAAA	CHRNA5	NM_000745.3
Hs00610231_m1	TCTTTAAAGGCTGTGTGGGCTGTGC	CHRNA6	NM_001199279.1
Hs01063373_m1	CTCTATAACAGTGCTGATGAGCGCT	CHRNA7	NM_001190455.2
Hs00395558_m1	TGCCCTGATAGGTAAATACTACAT	CHRNA9	NM_017581.3
Hs00220710_m1	TAACAAAGCCGACGCGCAGCCTCCA	CHRNA10	NM_020402.2
Hs00181267_m1	ACAACAATGCTGACGGCATGTACGA	CHRN2	NM_000748.2
Hs00181269_m1	TTGAAAATGCTGACGGCCGCTTCGA	CHRN3	NM_000749.3
Hs00181269_m1	CCTTTGCGGGCGCGGGAAGTCCGC	CHRN4	NM_001256567.1
Hs00609520_m1	GACTCATGACCACAGTCCATGCCAT	GAPDH	NM_001256799.1
Hs02758991_g1	AAGCAGCATCATGGAGGTTTGAAGA	B2M	NM_004048.2
Hs00984230_m1	GTGATCGTCACTTGACAATGCAGAT	UBC	NM_021009.5
Hs01060665_g1	CCCAGGCACCAGGGCGTGATGGTGG	ACTB	NM_001101.3

MOL #100982

Table 5

Comparison of α -Ctx IC₅₀ values for inhibition of rat vs human nAChRs expressed in *Xenopus* oocytes

	r α 3 β 4	h α 3 β 4	ratio	r α 6 β 4	h α 6 β 4	ratio
BuIA(T5A,P6O)	1.2 μ M ^a	166 nM ^d	7	58 nM ^a	7 nM ^d	8
MII[H9A,L15A]	7.8 μ M ^a	1.4 μ M ^b	6	269 nM ^a	13 nM ^b	21
PeIA(A7V,S9H,V10A,N11R,E14A)	>10 μ M ^c	3.7 μ M ^d	3	44 nM ^c	1.6 nM ^d	28
AuIB	750 nM ^e	>10 μ M ^d	-3	7.3 μ M ^f	360 nM ^d	20

r, rat; h, human; ratios compare rat/human

^a Azam et al. 2010

^b Hernandez-Vivanco et al. 2014

^c Hone et al. 2013

^d This work

^e Luo et al. 1998

^f Smith et al. 2014




Figure 1




Figure 2




Figure 3








Figure 4







Figure 5

Medullary Tissue



Molecular Pharmacology Fast Forward. Published on September 1, 2015 as DOI: 10.1124/molpharm.115.001111. This article has not been copyedited and formatted. The final version may differ from this pre-proof.

B



C




Figure 6

nAChR Gene Expression Relative to
GAPDH/ β -Actin

$\log_{10} 2^{-\Delta\Delta Ct}$




Figure 7




Figure 9